Newsroom

April 2017

• Press release Apr 28, 2017

  Novartis receives FDA approval for Rydapt® in newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of systemic mastocytosis (SM)

  Approval in newly diagnosed FLT3-mutated AML represents the first new treatment in more than 25 years[1],[2]  Rydapt treatment regimen in FLT3-mutated AML demonstrated a significant improvement…
• Press release Apr 26, 2017

  Alcon announces EU launch of CyPass® Micro-Stent, a micro invasive glaucoma surgical device, to lower intraocular pressure (IOP) in patients with primary open-angle glaucoma

  Now available in the UK, Germany, Italy and Spain, CyPass Micro-Stent is designed to significantly reduce intraocular pressure (IOP) CE indication has been expanded to allow patients to be…
• Press release Apr 25, 2017

  Novartis delivered sales growth across all divisions (cc1) as growth drivers, including Cosentyx and Entresto, more than offset generic erosion; innovation momentum continued

  Net sales grew 2% (cc, -1% USD), as growth drivers more than offset Gleevec/Glivec impact Cosentyx (USD 410 million, +136% cc) showing strong growth in all three indications Entresto (USD 84…
• Press release Apr 25, 2017

  Novartis: ventes en progression (tcc1) dans toutes ses divisions; les moteurs de croissance, Cosentyx et Entresto inclus, compensent l'érosion due aux génériques; l'innovation toujours en plein essor

  Chiffre d'affaires net en hausse de 2% (tcc, -1% en USD), car les moteurs de croissance ont plus que compensé l'impact de Gleevec/Glivec Cosentyx (USD 410 millions, +136% tcc):…
• Press release Apr 25, 2017

  Novartis erzielt Umsatzsteigerungen in allen Divisionen (kWk1), wobei Wachstumstreiber wie Cosentyx und Entresto die Einbussen durch Generika mehr als wettmachen; Innovationsdynamik setzt sich fort

  Der Nettoumsatz wächst um 2% (kWk, -1% USD), da die Wachstumstreiber die Einbussen bei Glivec/Gleevec mehr als wettmachen Cosentyx (USD 410 Millionen, +136% kWk) erzielt in allen drei Indikationen…
• Press release Apr 24, 2017

  Novartis expands global collaboration with Amgen to commercialize first-in-class AMG 334 (erenumab) program in migraine prevention in the US and Canada

  Novartis and Amgen to co-commercialize AMG 334 (erenumab) in the US; Novartis to gain exclusive rights in Canada Novartis retains commercial rights in rest of world; Amgen retains commercial…
• 
  Story Apr 24, 2017 Discovery

  Saving tumor suppressors from the shredder

  Novartis opens up a path of research to protect proteins that guard against cancer.

• Press release Apr 24, 2017

  Novartis real-world data at AAN confirms benefit of Gilenya® on four key measures of disease activity in relapsing MS

  Over 16 months, more than 75% of patients on Gilenya had either no relapses, no new or enlarged MRI lesions or no disability progression; around 58% showed brain shrinkage levels broadly within the…
• Press release Apr 21, 2017

  Sandoz proposed biosimilars rituximab and etanercept recommended for approval in Europe*

  Sandoz receives positive CHMP opinions for biosimilars rituximab and etanercept to treat immunological diseases.  Biosimilar rituximab also recommended to treat blood cancers Comprehensive…
• Press release Apr 19, 2017

  NIH study in NEJM shows Novartis drug eltrombopag as first-line therapy with standard treatment improves responses in severe aplastic anemia

  NIH study found 58% of patients with treatment-naïve severe aplastic anemia (SAA) achieved a complete response when eltrombopag was given at the initiation of and concurrently with standard…
• Press release Apr 18, 2017

  Novartis expands development programs for NASH through clinical collaboration with Allergan

  Phase IIb clinical trial to evaluate a combination of a Novartis FXR agonist and Allergan's cenicriviroc for NASH, a progressive  form of non-alcoholic fatty liver disease  There are…
• Press release Apr 18, 2017

  Novartis CAR-T cell therapy CTL019 receives FDA Breakthrough Therapy designation for treatment of adult patients with r/r DLBCL

  Designation prioritizes investigational CTL019 (tisagenlecleucel) as a potential treatment for adult patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL)  R/r DLBCL…